S&P 500   3,971.27 (-0.16%)
DOW   32,394.25 (-0.12%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
S&P 500   3,971.27 (-0.16%)
DOW   32,394.25 (-0.12%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
S&P 500   3,971.27 (-0.16%)
DOW   32,394.25 (-0.12%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
S&P 500   3,971.27 (-0.16%)
DOW   32,394.25 (-0.12%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
NASDAQ:NCNA

NuCana - NCNA Stock Forecast, Price & News

$0.85
+0.05 (+6.19%)
(As of 03/28/2023 04:00 PM ET)
Add
Compare
Today's Range
$0.81
$0.91
50-Day Range
$0.80
$1.69
52-Week Range
$0.52
$2.24
Volume
252,558 shs
Average Volume
158,608 shs
Market Capitalization
$44.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.67

NuCana MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
329.9% Upside
$3.67 Price Target
Short Interest
Healthy
0.28% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.07mentions of NuCana in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.53) to ($0.41) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.15 out of 5 stars

Medical Sector

436th out of 1,002 stocks

Pharmaceutical Preparations Industry

204th out of 488 stocks


NCNA stock logo

About NuCana (NASDAQ:NCNA) Stock

NuCana Plc engages in the development of technology platform for the treatment of patients with cancer. Its Protide technology consists of acelarin, NUC-3373 and NUC-7738. The company was founded by Hugh Stephen Griffith and Christopher Barry Wood on January 28, 1997 and is headquartered in Edinburgh, the United Kingdom.

Receive NCNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NuCana and its competitors with MarketBeat's FREE daily newsletter.

NCNA Stock News Headlines

BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
See More Headlines
Receive NCNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NuCana and its competitors with MarketBeat's FREE daily newsletter.

NCNA Company Calendar

Last Earnings
11/17/2021
Today
3/28/2023
Next Earnings (Estimated)
4/26/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NCNA
Fax
N/A
Employees
27
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$3.67
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+356.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-55,740,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.73 per share

Miscellaneous

Free Float
35,900,000
Market Cap
$41.91 million
Optionable
Not Optionable
Beta
1.29

Key Executives

  • Hugh Stephen Griffith
    Chief Executive Officer & Executive Director
  • Donald Munoz
    Chief Financial Officer
  • Elisabeth Oelmann
    Senior VP-Medical & Clinical Development
  • Jeffrey D. Bloss
    Chief Medical Officer
  • Theresa Margaret Bruce
    Senior Vice President-Clinical Operations













NCNA Stock - Frequently Asked Questions

Should I buy or sell NuCana stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NuCana in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" NCNA shares.
View NCNA analyst ratings
or view top-rated stocks.

What is NuCana's stock price forecast for 2023?

1 Wall Street research analysts have issued 12 month price targets for NuCana's stock. Their NCNA share price forecasts range from $2.00 to $6.00. On average, they predict the company's share price to reach $3.67 in the next twelve months. This suggests a possible upside of 356.5% from the stock's current price.
View analysts price targets for NCNA
or view top-rated stocks among Wall Street analysts.

How have NCNA shares performed in 2023?

NuCana's stock was trading at $0.66 at the start of the year. Since then, NCNA stock has increased by 21.7% and is now trading at $0.8032.
View the best growth stocks for 2023 here
.

Are investors shorting NuCana?

NuCana saw a increase in short interest in March. As of March 15th, there was short interest totaling 118,000 shares, an increase of 55.5% from the February 28th total of 75,900 shares. Based on an average trading volume of 141,000 shares, the days-to-cover ratio is presently 0.8 days. Currently, 0.3% of the company's stock are short sold.
View NuCana's Short Interest
.

When is NuCana's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 26th 2023.
View our NCNA earnings forecast
.

How were NuCana's earnings last quarter?

NuCana plc (NASDAQ:NCNA) posted its quarterly earnings data on Wednesday, November, 17th. The company reported ($15.00) earnings per share for the quarter, topping the consensus estimate of ($18.50) by $3.50.

What other stocks do shareholders of NuCana own?
When did NuCana IPO?

(NCNA) raised $100 million in an initial public offering (IPO) on Thursday, September 28th 2017. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Citigroup, Jefferies and Cowen served as the underwriters for the IPO and William Blair was co-manager.

What is NuCana's stock symbol?

NuCana trades on the NASDAQ under the ticker symbol "NCNA."

Who are NuCana's major shareholders?

NuCana's stock is owned by a number of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (0.63%) and Susquehanna International Group LLP (0.12%).

How do I buy shares of NuCana?

Shares of NCNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NuCana's stock price today?

One share of NCNA stock can currently be purchased for approximately $0.80.

How much money does NuCana make?

NuCana (NASDAQ:NCNA) has a market capitalization of $41.91 million. The company earns $-55,740,000.00 in net income (profit) each year or ($0.76) on an earnings per share basis.

How can I contact NuCana?

NuCana's mailing address is 3 Lochside Way, Edinburgh X0, EH12 9DT. The official website for the company is www.nucana.com. The company can be reached via phone at 441313571111 or via email at chris.brinzey@westwicke.com.

This page (NASDAQ:NCNA) was last updated on 3/28/2023 by MarketBeat.com Staff